Latest Breaking News On - Hannover medical - Page 6 : comparemela.com

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette

The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School

United statesTel avivOz adlerTel aviv sourasky medical centerInstitute for drugsIsraeli ministry of healthHannover medical school inHannover medical schoolYale school of medicineCompany or scisparcExchange commissionYale child study centerScisparc ltdFederal instituteMedical devicesHannover medical

Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks

Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Foster cityUnited statesMeaghan smithJacquie rossHeiner wedemeyerHannover medical schoolEuropean commissionGilead on twitter sciencesGilead sciences in liver diseaseGilead public affairsExchange commissionCommittee for medicinal products human useEuropean medicines agencyDepartment of gastroenterologyGilead sciences incClinical research for hepatitis

Gilead s Hepcludex Shows Sustained Efficacy, Safety In People With Chronic HDV At Week 96

Gilead s Hepcludex Shows Sustained Efficacy, Safety In People With Chronic HDV At Week 96
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Heiner wedemeyerDepartment of gastroenterologyGilead sciences incHannover medical schoolEuropean associationInfectious diseasesHannover medical

Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks - Gilead Sciences (NASDAQ:GILD)

Continued Treatment with Bulevirtide Shows Clinical Benefit and Sustained Viral Decline with Prolonged Treatment in Patients Originally Considered Partial- or Non-Responders Gilead Sciences, Inc. (NASDAQ:GILD)

Foster cityUnited statesHeiner wedemeyerHannover medical schoolGilead sciences incGilead sciencesExchange commissionGilead sciences in liver diseaseDepartment of gastroenterologyEuropean commissionBulevirtide shows clinical benefitSustained viral declineProlonged treatmentPatients originally consideredEuropean associationInfectious diseases

Newly discovered genetic defect disrupts bloo

Newly discovered genetic defect disrupts bloo
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesAngela deya martinezJessica platonRene platzerChristoph bockSamaneh zoghiDeutsche forschungsgemeinschaftRocio cabrera perezAnna tinnacherHang brunnerKarinr engelhardtLoic dupreLeo kagerAnna kinderkrebsforschung